Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.52), $0.18 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $127.39 million versus the consensus estimate of $119.38 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.